Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes
Specific immune therapy targeting residual areas of cancer cells may emerge as a powerful treatment strategy for head and neck squamous cell carcinoma (HNSCC). In order to define possible targets for immune therapy, we evaluated the frequency of two groups of tumor antigens - the RAGE and GAGE famil...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2002
|
| In: |
Acta oto-laryngologica
Year: 2002, Jahrgang: 122, Heft: 5, Pages: 546-552 |
| ISSN: | 1651-2251 |
| DOI: | 10.1080/00016480260092381 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/00016480260092381 |
| Verfasserangaben: | Karl Götte, Dirk Usener, Frank Riedel, Karl Hörmann, Dirk Schadendorf and Stefan Eichmüller |
| Zusammenfassung: | Specific immune therapy targeting residual areas of cancer cells may emerge as a powerful treatment strategy for head and neck squamous cell carcinoma (HNSCC). In order to define possible targets for immune therapy, we evaluated the frequency of two groups of tumor antigens - the RAGE and GAGE families - by means of reverse transcriptase polymerase chain reaction using primary HNSCCs ( n =28), mucosa specimens as normal controls ( n =10) and HNSCC cell lines ( n =6). By means of specific primer selection we could differentiate between RAGE-1, -2, -3 and-4, as well as between two groups of GAGE genes (GAGE-1,2,7 vs GAGE-3,4,5,6,8). While all mucosa tissues (from smokers and non-smokers) were negative for both antigen families, 24/28 investigated tumors were positive for up to 5 tumor antigens. Among the RAGE genes, RAGE-1-positive tumors were the most abundant (8/28), followed by RAGE-2 (7/28) and RAGE-4 (6/28). Differences in the locations of HNSCCs were reflected by different RAGE family members being expressed most frequently: larynx, RAGE-1; oropharynx, RAGE-2; and hypopharynx, RAGE-4. Primers against GAGE-1,2,7 and GAGE-3,4,5,6,8 revealed 6/27 and 16/27 positive tumors, respectively. This report suggests that RAGE genes and GAGE-3,4,5,6,8 may be promising candidates for specific immune therapy in HNSCC. |
|---|---|
| Beschreibung: | Elektronische Reproduktion der Druckausgabe Gesehen am 17.11.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1651-2251 |
| DOI: | 10.1080/00016480260092381 |